BrainStorm to Present at Multiple Scientific Conferences in October

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it is presenting at multiple scientific conferences this month.

Israel Stem Cell Society 5thInternational Stem Cell Meeting

Professor Dani Offen, BrainStorms Chief Scientific Advisor, will present at the 5th International Stem Cell Meeting sponsored by the Israel Stem Cell Society, October 8th-9th in Jerusalem. Prof. Offen will be making a poster presentation on October 8th at 17:30, and an oral presentation on Oct 9th at 17:15.

Israel Braintech 2013

Professor Dani Offen, BrainStorms Chief Scientific Advisor, will present at the Israel Braintech 2013 Meeting, October 14th-15th in Tel Aviv. The meeting is sponsored by Israel Brain Technologies (IBT), a non-profit organization inspired by the vision of Israeli President Shimon Peres to promote Israels neurotechnology innovation hub. Prof. Offens oral presentation will be part of the session entitled: A Spotlight on the Israeli NeuroTech Industry, October 15th at 12:15.

Israel A.L.S Research Association

Professor Dimitrios Karussis, Principal Investigator of BrainStorms clinical trials at Jerusalems Hadassah Medical Center, will present at the Israel A.L.S Research Association (IsrA.L.S) Conference, From the Lab to the Clinic: An Overview of Current ALS Research in Israel, to be held October 30th at the Weizmann Institute of Science, Rechovot, Israel. Prof. Karussis oral presentation will be at 10:45 a.m.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

View post:
BrainStorm to Present at Multiple Scientific Conferences in October

Q Therapeutics CEO to Present at Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa

SALT LAKE CITY, UT--(Marketwired - Oct 8, 2013) - Q Therapeutics, Inc., an emerging biotechnology company developing innovative cell therapy products for the treatment of debilitating diseases of the central nervous system, today announced that Deborah Eppstein, PhD, President and CEO, is scheduled to present at the Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa.

The 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures.The meeting features a nationally recognized Scientific Symposium, attended by leading scientists and researchers, in conjunction with the industry's premier annual Regen Med Partnering Forum.Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.

EVENT AT A GLANCE:

Date: October 14, 2013

Time: 11:45 AM PT

Location: Estancia La Jolla Hotel & Spa La Jolla Ballroom AB 9700 North Torrey Pines Road La Jolla, California

To learn more or to register for the Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa, please visit http://www.stemcellmeetingonthemesa.com.Registration is required.

About Q Therapeutics, Inc. Headquartered in Salt Lake City, Utah, Q Therapeutics, Inc. is a fully reporting, non-trading company, engaged in developing adult stem cell therapies to treat debilitating diseases of the central nervous system.The Company's first product, Q-Cells, is a cell-based therapeutic intended to restore or preserve normal activity of neurons by providing essential support functions that occur in healthy central nervous system tissues.Q-Cells may be applicable to a wide range of central nervous system diseases, including demyelinating conditions such as multiple sclerosis, transverse myelitis, cerebral palsy and stroke; as well as other neurodegenerative diseases and injuries, such as ALS (Lou Gehrig's disease), spinal cord injury, Parkinson's disease and Alzheimer's disease.Q Therapeutics' initial clinical target is ALS, with a first IND submission expected in 2014.For more information, visit http://www.qthera.com.

Read the original post:
Q Therapeutics CEO to Present at Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa

Stem cells delivered by patch repair damage after cardiac arrest

Stem cells delivered by patch effective in repairing cardiac damage weeks after heart attack occurs

A new study released in STEM CELLS Translational Medicine shows that in rats, treating a heart attack with stem cells even weeks after the attack occurred can halt deterioration and help the heart regenerate itself. In addition, the doctors delivered the cells using a patch that resulted in a higher survival rate for the stem cells and more of them migrating into the damaged tissue, where they went to work creating new blood vessels.

The team, from the University of Louisvilles Cardiovascular Innovation Institute (Louisville, KY), had previously shown in rat studies that stem cell treatment immediately following an attack aided recovery by improving blood flow in the smallest vessels of the heart. This time the goal was to determine if the treatment was still effective if applied later in time.

We also were seeking a more efficient delivery method for the stem cells by utilizing the heart patch model. Most studies employing an injection of stem cells encounter swift cell death or cell washout from the target tissue, said Amanda LeBlanc, Ph.D., who led the investigation along with Stuart Williams, Ph.D., the institutes executive and scientific director.

They tested their theory by applying a patch seeded with stem cells harvested from the animals own adipose (fat) tissue and then cultured in the lab. They implanted the seeded patches into one group of rats two weeks after the animals had a heart attack, while another group received the patch without stem cells (to gauge whether any effects might be due to the body's response to a foreign material or whether the biomaterial itself was helping the heart pump more efficiently, regardless of cells). Two more groups of rats with induced heart attacks were given no treatment, and were carried out for two and six weeks as controls.

This approach allowed us to study the progressive and sometimes irreversible pathological changes that occur weeks to months following an attack, such as cellular death, the beginning of scar tissue formation and thinning of the outer left ventricle wall, Dr. Williams explained.

When they compared the results, they found that the cell patch treatment indeed stabilized the heart, preventing or halting any worsening of cardiac function and restoring blood flow to the small blood vessels. This is why I refer to our cell patch as a pause button, because once it was applied the heart didn't progress into worse function like the patch group without cells and the untreated six-week group, Dr. LeBlanc said.

That led us to conclude that the clinical potential of an autologous patch that is, a patch seeded with the patients own stem cells using adipose-derived cells is high, as the patch may be used in conjunction with existing heart attack therapies to promote small vessel survival and/or growth of new vessels following the attack, she added.

This study, and the authors previous research, both in rats, lays important groundwork in addressing such issues as the best delivery method of cells and how long after a heart attack treatment might be beneficial, said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

STEM CELLS Translational Medicine

Follow this link:
Stem cells delivered by patch repair damage after cardiac arrest

Global Stem Cells Group, Inc. Announces Launch of Plasma Plus Platelet Rich Plasma Therapy Services in Dominican …

Miami (PRWEB) October 07, 2013

The Global Stem Cells Group, Inc. has announced the launch of Plasma Plus medical services company in the Dominican Republic. Plasma Plus provides certified medical professionals, top of the line equipment, FDA approved protocols for hospitals, clinics and physicians, and protocol-specific equipment and consumables for application of platelet rich plasma therapy (PRP.)

Plasma Plus also assigns a qualified, certified health care professional to perform the PRP extraction and preparation procedures. Clients need only apply the therapy where needed to achieve the rejuvenating, regenerating and revitalizing results of PRP therapy, eliminating excess overhead costs, need for equipment purchases and preoccupation with maintaining protocol standards.

The benefits of PRP treatments extend through a wide and diverse group of medical fields, from cosmetic surgery to dentistry; Plasma Plus is committed to making PRP an available and cost-effective treatment option for medical professionals.

The companys product line includes:

The Plasma Plus equipment line includes:

For more information on Plasma Plus medical services, products and equipment, visit the Plasma Plus website, email info(at)www(dot)plasmaplusonline(dot)com(dot)do or call 849.943.2988.

About Plasma Plus:

Plasma Plus is an innovative, turn-key medical service company providing certified professionals, state-of-the-art equipment, and FDA approved protocols and kits for application of platelet rich plasma therapy (PRP). Plasma Plus technicians are trained and certified by a qualified team of medical professionals that includes physicians and nurses. Staffed by physicians, medical consultants and leading scientific researchers in the field to provide patients with the leading platelet rich plasma therapy.

PRP treatments utilize the bodys own resources to stimulate growth and regeneration with an overabundance of growth factors derived from platelets.

See original here:
Global Stem Cells Group, Inc. Announces Launch of Plasma Plus Platelet Rich Plasma Therapy Services in Dominican ...

BrainStorm to Present at 2013 Stem Cell Meeting on the Mesa Organized by CIRM, ARM and Sanford Consortium

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dr. Adrian Harel, Director R&D, will present at the 3rd Annual Regen Med Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 14-16 in La Jolla, CA.

Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The Regen Med Partnering Forum, held October 14 & 15 at the Estancia La Jolla Hotel, is the only partnering meeting organized specifically for the regenerative medicine and advanced therapies industry.

The meeting also features a nationally recognized Scientific Symposium, held October 16 at the Salk Institute for Biological Studies, showcasing leading academic research in the field of regenerative medicine. Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.

The following are specific details regarding BrainStorms presentation at the conference:

Event: Regen Med Partnering Forum 2013 Stem Cell Meeting on the Mesa Date: Monday, October 14, 2013 Time: 10:45 am Location: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037

A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on ARMs website shortly after the event.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

Safe Harbor Statement

Visit link:
BrainStorm to Present at 2013 Stem Cell Meeting on the Mesa Organized by CIRM, ARM and Sanford Consortium

Leading experts offer advice on generating human induced pluripotent stem cell banks

Public release date: 3-Oct-2013 [ | E-mail | Share ]

Contact: Mary Beth O'Leary moleary@cell.com 617-397-2802 Cell Press

The ability to make induced pluripotent stem cells (iPSCs) from mature cells in the body holds great potential for improved drug screening, disease modeling, and medical treatments for numerous conditions. Establishing well-characterized panels of iPSC lines that reflect the diversity of the human population and include samples from patients with a wide range of diseases will be key to tapping into the potential of iPSCs. In the October 3 issue of the Cell Press journal Cell Stem Cell, leading experts in the field publish several opinion pieces on emerging issues related to generating such iPSC banks, and they provide practical recommendations and creative solutions to address challenges associated with such large-scale efforts.

Dr. Glyn Stacey of the National Institute for Biological Standards and Control, located in the United Kingdom, and his colleagues recommend approaches for utilizing the knowledge of existing, well-established human embryonic stem cell banks and their experience in standardization to promote quality control in iPSC resource centers. "Not all laboratories will have the same level of expertise in cell culture or familiarity with vital quality control procedures. These will be essential to avoid the circulation of iPSC lines that have become contaminated or switched with other cell lines," says Dr. Stacey. "Such events can lead to fundamental flaws in the published literature and a waste of precious research resources."

In another Forum, Dr. Mahendra Rao, who is the director of the intramural Center for Regenerative Medicine at the National Institutes of Health, reiterates that making iPSC lines and developing the requisite controls and tests is time consuming, expensive, and generally beyond the expertise of any single laboratory. "Fulfilling the expectations for iPSCs and their use will only be possible if we develop a new cost-effective way to share and distribute cell lines. Crowd sourcing is one solution," he says. For the model to be successful, it must be self-sustaining. "Technology holders must buy in to the idea that it will ultimately benefit them as well as the users. It would also be important to ensure that expertise existed in the various repositories to store, characterize, test, and track the cells and their derivatives and that the repositories could do so at costs that were reasonable for the end user," writes Dr. Rao.

Finally, Dr. Ian Wilmut and his colleagues present a piece that addresses important considerations for immune matching between iPSC donors and recipients. They note that while it is possible that iPSC lines could be derived on an individual basis -- so that an individual patient would receive his or her own cells as a treatment -- it seems unlikely that this method would be used as a source for large numbers of patients in the near future due to time and cost restraints. A more practical solution is to build a bank of stem cell lines from a small pool of individuals that match a majority of the patient population and could be safely transplanted without immune rejection. "Calculations suggest that cells from approximately 150 selected people would provide a useful immunological match for the majority of people," explains Dr. Wilmut. "We propose that an international network of stem cell banks working with common procedures and standards should be established now in order to provide the broadest range of immunological types. This would be a critical step in ensuring widespread availability of high quality cell therapies in the future."

###

Cell Stem Cell, Turner et al.: "Towards The Development of a Global Induced Pluripotent Stem Cell Library."

Cell Stem Cell, Rao et al.: "iPSC Crowdsourcing: A Model for Obtaining Large Panels of Stem Cell Lines for Screening."

Cell Stem Cell, Stacey et al.: "Banking Human Induced Pluripotent Stem Cells: Lessons Learned from Embryonic Stem Cells?"

Originally posted here:
Leading experts offer advice on generating human induced pluripotent stem cell banks

Researchers unveil method for creating 're-specified' stem cells for disease modeling

Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript. In order to enable it, please see these instructions. 19 hours ago

In a paper in Cell Stem Cell, a team led by researchers in the Boston Children's Hospital's Stem Cell Transplantation Program reports a new approach for turning induced pluripotent stem cells (iPSCs) into hematopoietic stem and progenitor cells for in vivo disease modeling.

With this strategywhich they call re-specificationthe team, including Sergei Doulatov, PhD, and George Daley, MD, PhD, of Boston Children's, may have overcome technical barriers to generating blood disease-specific animal models from the thousands of iPSC cell lines now sitting in laboratory freezers around the world.

The main advantage of the technique lies in the raw material. The research team started with iPSCs that had already been directed to grow into myeloid progenitors, which are more closely related to the desired blood progenitors than skin or other fully differentiated cell types commonly used in stem cell experiments.

The researchers then used a select set of transcription factors to turn back the molecular clock just a little on these committed myeloid cells, turning them into blood progenitors that readily engrafted and differentiated when transplanted into mice.

The re-specification technique could help generate the large number of engraftable cells needed to create animal models from iPSCs generated from human patients suffering a range of blood disorders, such as anemias, thalassemia or sickle cell disease.

Explore further: Scientists identify key regulator controlling formation of blood-forming stem cells

Stem cell scientists have moved one step closer to producing blood-forming stem cells in a Petri dish by identifying a key regulator controlling their formation in the early embryo, shows research published online today in ...

Liver transplantation is the mainstay of treatment for patients with end-stage liver disease, the 12th leading cause of death in the United States, but new research from the Icahn School of Medicine at Mount Sinai, published ...

Massachusetts General Hospital (MGH) researchers have used vascular precursor cells derived from human induced pluripotent stem cells (iPSCs) to generate, in an animal model, functional blood vessels that lasted as long as ...

Read the original post:
Researchers unveil method for creating 're-specified' stem cells for disease modeling

UFC Contender Cat Zingano Will Undergo Stem Cell Procedure for Left Knee

Top ranked UFC bantamweight challenger Cat Zingano has been out of action for several months due to an injury to her right knee. That injury is on the mend, but it has led to issues with her left knee, for which Zingano will have a procedure on Thursday.

I am about three and a half months out (from the original injury), Zingano said on UFC Tonight. I went to my doctor on Monday. He said that Im right on track, so I should be coming back in another four months, something like March or April.

That is, of course, as long as the issues with her left knee can be rectified within that same time frame, which her doctor believes is the case.

Dr. Ronald S. Kvitne of the Kerlan-Jobe Orthopedic Clinic in Los Angeles on Monday told Zingano that if there was a tear in her left meniscus, as expected, that if they act quickly, it shouldnt extend the rehab time of her original injury.

Dr. Kvitne was initially thinking a surgery would be necessary, but Zingano on Wednesday indicated that Thursdays procedure would instead involve a stem cell treatment.

My left knee, because I think for the compensation for taking care of my right knee, has been taking a little bit more wear and tear than it was used to, said Zingano.

So Im going to have a procedure done with stem cells (on Thursday) that is going to be in place of having clean-up surgery instead.

If Zinganos rehabilitation remains on schedule, she would be able to return to the Octagon and fight sometime around April of 2014.

We think three months from now shed be back in the ring training, sparring, said Kvitne. So fighting in about four to six months from now.

Zingano also told UFC Tonight that she should expect to fight the winner of the Dec. 28 rematch between current UFC bantamweight champion Ronda Rousey and challenger Miesha Tate upon her return.

View original post here:
UFC Contender Cat Zingano Will Undergo Stem Cell Procedure for Left Knee

FDA says StemCells can expand clinical trial to US

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? Nightline Fix Beyond the Headline Local Popular Search Keyword News Search

See original here:
FDA says StemCells can expand clinical trial to US

Research on treatment for ALS aided by stem cells

Though the Food and Drug Administration remains closed due to the federal government shutdown, researchers at the University are pushing forward the development of stem-cell therapies, with the hope of improving the quality of life for individuals with life-threatening disabilities.

Researchers at University Hospital and the A. Alfred Taubman Medical Research Institute are exploring the use of stem cells in the treatment of amyotrophic lateral sclerosis also known as Lou Gerhigs disease, a neurodegenerative condition that causes cell death in spinal cord neurons that control movement. Patients with ALS suffer from loss of muscle control and often die of respiratory failure.

Neurology Prof. Eva Feldman presented recent results from her research at an event Wednesday evening at the Taubman Institutes Kahn Auditorium for an audience of about 40 students and faculty. Feldman discussed the completion of Phase I trials of the new stem-cell therapy and her plans for Phase II.

While Phase I trials typically test the safety of a treatment in human patients, Phase II tests the treatments efficacy. Feldmans research team received approval for Phase II of their research in May and has since begun tests.

Shortly before the event Wednesday afternoon, a third patient enrolled in the trial had the surgical procedure, in which a surgeon injects stem cells into specific regions of the spinal cord. Although it is too early to record changes in disease progression, Feldman said the three patients have experienced no adverse consequences from the procedure.

Stem cells have the unique ability to fulfill a wide variety of tasks by developing into specialized cells depending on their environment. When these cells are injected into the spinal cord of ALS patients, they surround diseased cells and slow the progression of cell death, Feldman said.

Depending on how you grow them they can become any cell in the body, Feldman said.

Feldmans treatment uses a relatively new strain of human embryonic stem cells developed at the University through partnerships with the National Institutes of Health. She referenced the work of Physiology Prof. Gary Smith at MStem Cell Laboratories the Universitys stem cell institution as a crucial component to the development of the treatment.

What weve done here at the University of Michigan is make embryonic stem cell lines, which are now being used for understanding disease course as well as for treatment, Feldman said.

Stem cells have the potential to aid in the treatment of not only ALS, but a wide range of debilitating and life-threatening diseases, including Parkinsons disease, Alzheimers disease and multiple sclerosis, Feldman said.

Read the rest here:
Research on treatment for ALS aided by stem cells